Wellion

Wellion INOVO FIA Analyzer
SARS-CoV-2 antibody detection
in only 15 minutes

    Wellion INOVO FIA Analyzer

    SARS-CoV-2 antibody determination

    Reliable test result in BAU/mL with only one finger prick in 15 min!

     

    The Wellion INOVO FIA Analyzer in compact benchtop format allows a fast and easy SARS-CoV-2 antibody determination. With only one finger prick (20µl capillary blood) the evaluation can be done directly on site in only 15 minutes.

     

    •     Quick

    •     User-friendly - easy operation

    •     Compact benchtop format

    •     Easy on-site determination

    •     Large, clear touch screen

    •     Integrated thermal printer - results can be taken away immediately

    •     3 different test options, depending on need and frequency

      •     Standard

      •     Quick

      •     Serial test

     

    SARS-CoV-2 antibody detection - The reliable test result to take home

    • Checking the immune response

    • Determination of SARS-CoV-2 S antibodies (spike antibodies*)

    • Result in only 15 minutes

    • No waiting time - evaluation right on the spot

    • Small amount of blood (20 µl)

    • Convenient measurement with capillary blood (finger prick with safety lancet)

    • Quantitative information in BAU/mL

     

     

     

    Scheme of the different test procedures for the SARS-CoV-2 antibody test with the Wellion INOVO FIA Analyzer

     

    1. Test preparation

    2. Incubation and measurement

      • Standard (STD) - timecode 3:51

      • Instant - timecode 04:51

      • Batch - timecode 07:30

     

    Specifications

    • Measurement of SARS-CoV-2 S antibodies*

    • Quantitative result in BAU/mL (= WHO standard)

    • Reliable - performance data for whole blood from finger prick:

      • Sensitivity: 98,22%

      • Specificity: >99,99%

      • Accuracy: 99,39%

    • 25 tests/kit

    • 24 months shelf life

    • Storage at room temperature

    • Calibration by code chip (included in test kit)

     

    *Spike (S)-glycoprotein is the main target of neutralisation by SARS-CoV-2 antibodies and thus the basis for vaccine development.

    Approved for professional use only.